Clinical Trial

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Study acronym: CRISP
Recruiting
View on ClinicalTrials.gov →
Summary
Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2015-12-03; most recent amendment 2025-02-14.
Status change: Not Yet Recruiting → Recruiting 2016-01-04
Trial Details
NCT Number NCT02622581
Lead Sponsor AIO-Studien-gGmbH
Collaborators: AstraZeneca, Celgene Corporation, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, iOMEDICO AG, Eli Lilly and Company, Roche Pharma AG, Takeda, Amgen, Janssen-Cilag G.m.b.H, GlaxoSmithKline, Daiichi Sankyo, Regeneron Pharmaceuticals, Gilead Sciences
Conditions Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage II, Non Small Cell Lung Cancer Stage III, Small-cell Lung Cancer, Non-small Cell Lung Cancer Stage I
Enrollment 12,400 participants
Start Date 2015-12
Primary Completion 2026-09 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-18